Ora

🚀 Things move fast in ophthalmology and we’re here for it. From gene therapies to sustained delivery and AI-driven insights, the pace of innovation in our field is nothing short of staggering. Every year, what once felt like the future starts showing up in real-world clinics. That’s what makes days like Eyecelerator so exciting. It’s where the ideas, the science, and the people driving this rapid change all come together. At Ora, we’ve always believed in moving quickly, not just for the sake of speed, but to help transformative ideas reach patients who need them most. Here’s to another day of inspiration and seeing what’s next for ophthalmic innovation. 👁️⚡ #Eyecelerator #AAO2025 #OphthalmologyInnovation #ClinicalResearch #TeamOra #EyeCare

Shared values. Shared impact. 🌍 Vistria has just released their 2025 Impact Report, and it’s a great reflection of why we’re proud to have them as our majority investor. It's an honour to be featured among the healthcare innovators helping bring lasting impact to patients’ lives. Their focus on long-term partnerships, sustainable growth, and improving patient outcomes aligns perfectly with what drives us every day at Ora. For us, impact isn’t a buzzword, it’s the reason we do what we do. Seeing that same commitment echoed at the investor level is both encouraging and energising as we continue our mission to advance ophthalmic science and improve lives. You can read the full report here: https://hubs.la/Q03NqzJV0 #ImpactInvestment #ClinicalResearch #Ophthalmology #PatientOutcomes #HealthcareInnovation #TeamOra

👁️ Happy World Sight Day! "To those of you out there in clinical research, thank you for seeing the blindness community." Today’s a moment to pause and appreciate everyone working to preserve and restore sight. From the sponsors driving innovation, to the investigators and site teams delivering the studies, and to the patients whose experiences inspire us all to do better. A special thank you to Ben Fox and the Blind Canvas Project, whose advocacy and insight continually remind us that behind every data point is a person, a story, and a future worth seeing. We’re proud to play our part alongside so many of you in helping turn that vision into reality. #WorldSightDay #Ophthalmology #CRO #ClinicalResearch #PatientFocus #BlindCanvasProject #TeamOra

Protecting your vision starts with understanding it. 👁️ The latest feature on OraConnects explores Neurotrophic Keratitis (NK), a rare eye condition that can quietly affect the cornea’s ability to heal. Because NK often develops without obvious symptoms, awareness is key. The blog breaks down what causes it, how it’s diagnosed, and why early detection can make such a difference for long-term vision health. It’s all part of our commitment to helping patients, families, and clinicians better understand the complex conditions that impact sight. 💡 Read more: Neurotrophic Keratitis: Protecting Your Vision 🔗https://hubs.la/Q03MJhGq0 #EyeHealth #Ophthalmology #PatientAwareness #NeurotrophicKeratitis #OraConnects #Ora

👏 A milestone to celebrate: First Patients Dosed! We’re proud to share that our study team has successfully randomised and dosed not just one, but two patients on the same day with Belgium leading the way, closely followed by the US. 🌍✨ This global phase three trial is for a therapy which targets a rare inherited retinal disease that causes severe vision loss from childhood. With no approved treatments currently available, progress in this area has the potential to make a meaningful difference for patients and families worldwide. This milestone is the result of fantastic transatlantic collaboration, showcasing the dedication, resilience, and determination of everyone involved. A big thank you to the entire team for bringing us one step closer to new possibilities in retinal research. #ClinicalTrials #InheritedRetinalDisease #RetinalResearch #OphthalmologyResearch #TeamOra

Slowing vision loss before it happens — that’s the task with Geographic Atrophy in advanced AMD. ⏳👁️ The challenge? Slowing disease progression is subtle and gradual, making it difficult to demonstrate the impact of preventative therapies in clinical trials. Capturing meaningful endpoints requires precision, consistency, and long-term follow-up. Our approach: At Ora, we leverage advanced imaging, standardized protocols, and global trial expertise to deliver high-quality, reliable data. By navigating these complexities, we support sponsors in developing therapies that preserve vision before irreversible damage occurs. Because in retinal research, preventing vision loss is just as critical as treating it. #IndicationSpotlight #AMD #GeographicAtrophy #PreventativeMedicine #RetinalResearch #ClinicalTrials #TeamOra

Just 2 weeks until AAO 2025, and the Ora team is gearing up for a week of science, connections and a few twists and turns along the way! 🎢✨ Ophthalmic development can feel a bit like a theme park ride: unexpected loops, rapid progress, and sometimes just a touch of nausea. At Ora, we thrive on guiding trials smoothly through every twist and turn, helping bring innovative therapies to patients safely and efficiently. Our team will be on the ground in Orlando and can't wait to help advance ophthalmic science. Will we see you there? 👉 Arrange a meeting with our team: https://hubs.la/Q03JY60Q0 #AAO2025 #TeamOra #OphthalmologyInnovation #RetinalResearch #ClinicalTrials

From myopia and hyperopia to presbyopia and astigmatism — refractive conditions (dubbed by this LinkedIn admin as the “-opias”) affect billions of people worldwide and remain one of the leading drivers of vision correction needs. 👓 The challenge? Each condition presents unique hurdles. From diverse patient populations and progression rates to the need for precise measurement and consistent endpoints. Paediatric trials add another layer of complexity, requiring specialised expertise in study design, recruitment, and patient engagement. Our approach: At Ora, we design and execute refractive trials with meticulous attention to accuracy and consistency across all age groups. With extensive experience in paediatric myopia studies, as well as adult refractive research, we bring the expertise and global infrastructure needed to deliver reliable results. Because advancing innovation in refractive care means bringing clarity in more ways than one. #IndicationSpotlight #Refractive #Myopia #Presbyopia #PaediatricTrials #OphthalmologyResearch #ClinicalTrials #Ora

Consistency is key when conducting clinical trials across the world. How do we maintain uniformity- and ensure success- across global clinical trials? To conclude our miniseries on the obstacles faced in clinical trials, we will be exploring how we maintain consistency in trials across the globe. From implementing a standardized project management approach to understanding and navigating local complexities, we will help you succeed no matter where in the world you may be. #ClinicalTrials #Ophthalmology #LifeSciences #ClinicalResearch #DrugDevelopment #MedicalInnovation #TeamOra #GlobalTrials #ProjectManagement #ConsistencyInResearch

Emerging, challenging, and critical: Thyroid eye disease is one of the newest frontiers in Ora’s portfolio. The challenge: TED’s wide-ranging symptoms and variable progression make consistent endpoints and reliable measurements tough to achieve. Our approach: Ora combines deep ophthalmic trial expertise with rigorous imaging, clinical assessments, and standardised protocols to bring clarity to this complex indication. By partnering closely with investigators and sponsors, we help accelerate therapies that improve outcomes for patients living with TED. From our roots in ocular allergy to emerging indications like TED, Ora continues to lead with innovation and patient focus. #IndicationSpotlight #ThyroidEyeDisease #OphthalmologyResearch #ClinicalTrials #TeamOra